MEN4901/T-0128, a new camptothecin derivative-carboxymethyldextran conjugate, has potent antitumor activities in a panel of human tumor xenografts in nude mice

Clinical Cancer Research

Volumn 11, Issue 4, 2005, Pages 1650-1657

  Fujita, Fumiko ^a,b,e   Koike, Masako ^a   Fujita, Masahide ^b,e   Sakamoto, Yasuo ^b,e   Okuno, Satoshi ^c   Kawaguchi, Takayuki ^c   Yano, Shigeru ^c   Yano, Toshiro ^c   Kiuchi, Satoko ^c   Fujiwara, Toshihisa ^c   Kudoh, Shinzoh ^b,d   Kakushima, Masatoshi ^c  

^a Exp Cancer Chemother Res L C L

^b Assoc for Anticancer Drug Search   (Japan)

^c MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^d Osaka City University   (Japan)

^e OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN DERIVATIVE; CARBOXYMETHYLDEXTRAN; IRINOTECAN; MEN 4901; T 0128; T 2513; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN H 110; CELL STRAIN H 181; CELL STRAIN H 204; CELL STRAIN H 48; CELL STRAIN H 81; CELL STRAIN H74; CELL STRAIN MQNU 1; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TUMOR LEVEL; FEMALE; HUMAN; HUMAN CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MOUSE; MOUSE STRAIN; MOUSE STRAIN BALB C AJCL; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; STOMACH CARCINOMA; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BODY WEIGHT; CAMPTOTHECIN; CELL LINE, TUMOR; DEXTRANS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; TIME FACTORS; TOPOTECAN; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 20044379959     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1756     Document Type: Article

References (24)

1. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988;48:1722-6.
2. Slichenmyer WJ, Rowinsly EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993;85:271-91.
3. Greenwald RB, Pendri A, Conover C, Gilbert C, Yang R, Xia J. Drug delivery systems. 2. Camptothecin 20-O-poly(ethylene glycol) ester transport forms. J Med Chem 1996;39:1938-40.
4. Caiolfa VR, Zamai M, Fiorino A, et al. Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. J Control Release 2000;65:105-19.
5. Okuno S, Harada M, Yano T, et al. Complete regression of xenografted human carcinoma by camptothecin analogue-carboxymethyldextran conjugate (T-0128). Cancer Res 2000;60:2988-95.
6. Lerchen HG, Baumgarten J, von dem Bruch K, et al. Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents. J Med Chem 2001;44:4186-95.
7. Singer JW, Bhatt R, Tulinsky J, et al. Water-soluble poly-(L-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo. J Control Release 2001;74:243-7.
8. Inoue K, Kumazawa E, Kuga H, et al. CM-dextran-polyalcohol-camptothecin conjugate: DE-310 with a novel carrier system and its preclinical data. Adv Exp Med Biol 2003;519:145-53.
9. Hashida M, Takakura Y. Pharmacokinetics in design of polymeric drug delivery systems. J Control Release 1994;31:163-71.
10. Conover CD, Greenwald RB, Pendri A, Shum KL. Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs. Anticancer Drug Des 1999;14:499-506.
11. Zamai M, VandeVen M, Farao M, et al. Camptothecin poly[n-(2- hydroxypropyl) methacrylamide] copolymers in antitopoisomerase-I tumor therapy: intratumor release and antitumor efficacy. Mol Cancer Ther 2003;2:29-40.
12. Harada M, Sakakibara H, Yano T, Suzuki T, Okuno S. Determinants for the drug release from T-0128, camptothecin analogue-carboxymethyldextran conjugate. J Control Release 2000;69:399-412.
13. Kaneda N, Nagata H, Furuta T, Yokokura T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 1990;50:1715-20.
14. Fujita F, Fujita M, Taguchi T, et al. Multifactorial analysis of parameters influencing chemosensitivity of human cancer xenografts in nude mice. Int J Cancer 1989;43:637-44.
15. Fujita F, Koike M, Fujita M, Sakamoto Y, Tsukagoshi S. Antitumor effects of TZT-1027, a novel dolastatin 10 derivative, on human tumor xenografts in nude mice. Jpn J Cancer Chemother 2000;27:451-8.
16. Koike M, Fujita F, Komori K, et al. Dependence of chemotherapy response on p53 mutation status in a panel of human cancer lines maintained in nude mice. Cancer Sci 2004;95:541-6.
17. Kubota T, Nakada M, Tsuyuki K, et al. Cell kinetics and chemosensitivity of human carcinomas serially transplanted into nude mice. Jpn J Cancer Res 1986;77:502-7.
18. Houchens DP, Ovejera AA, Sheridan MA, et al. Therapy for mouse tumors and human tumor xenografts with the antitumor antibiotic AT-125. Cancer Treat Rep 1979;63:473-6.
19. Tamura T, Fujita F, Tanimoto M, et al. Anti-tumor effect of intraperitoneal administration of cisplatin-loaded microspheres to human tumor xenografted nude mice. J Control Release 2002;80:295-307.
20. Shimosato Y, Oboshi S, Baba K. Histological evaluation of effects of radiotherapy and chemotherapy for carcinomas. Jpn J Clin Oncol 1971;1:19-35.
21. Cassidy J, Newell DR, Wedge SR, Cummings J. Pharmacokinetics of high molecular weight agents. Cancer Surv 1993;17:315-41.
22. Qian F, Bajkowski AS, Steiner DF, Chan SJ, Frankfater A. Expression of five cathepsins in murine melanomas of varying metastatic potential and normal tissues. Cancer Res 1989;49:4870-5.
23. Fujita M, Fujita F, Sakamoto Y, Sugimoto T, Shimozuma K, Taguchi T. Predictability of preclinical evaluation of anticancer drugs by human gastrointestinal cancer-nude mouse panel. Jpn J Cancer Chemother 1991;18:1429-37.
24. Fujita M, Hayata S, Taguchi T. Relationship of chemotherapy on human cancer xenografts in nude mice to clinical response in donor patient. J Surg Oncol 1980;15:211-9.